Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Next Previous
Trial Profile

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMA-203 (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Solid tumours; Synovial sarcoma; Triple negative breast cancer; Uterine cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms ACTengine
  • Sponsors Immatics US

    • Most Recent Events

    • 02 Nov 2023 Planned number of patients changed from 186 to 270.
    • 23 Sep 2023 Results assessing the safety and anti -tumor activity of IMA203 TCR -Tin patients with recurrent/refractory solid tumors, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
    • 21 Aug 2023 Planned number of patients changed from 172 to 186.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top